IP Library Granted Patent US 10,226,484
Granted Patent B2
US 10,226,484 · App. 15/613,109 · Granted Mar 12, 2019

Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof

Inventors: Peter Y Novak (Sunny Isles Beach, FL); Maxim V Temnikov (Miami, FL); Oleksandr Balakin (Dnepropetrovsk, UA)
A61K33/30A23L33/10A61K31/704A61K33/00A61K33/06A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,484
App. No.
15/613,109
Granted
Mar 12, 2019
Kind
B2
Abstract

A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 %. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.

Claims (10)

1. A therapeutic composition comprising at least one excipient and an effective amount of 64 Zn-enriched zinc, wherein the 64 Zn-enriched zinc is present as a chelate of an amino acid, wherein the 64 Zn-enriched zinc is at least 80% 64 Zn.

2. The composition of claim 1 , wherein the 64 Zn-enriched zinc is at least 90% 64 Zn.

3. A therapeutic composition comprising 64 Zn-enriched zinc wherein the 64 Zn-enriched zinc is at least 90% 64 Zn and is present as a chelate of an amino acid, and the composition contains between 0.6 mg and 330 mg of 64 Zn.

4. The composition of claim 3 , wherein the composition contains between about 2 mg and about 110 mg of 64 Zn.

5. The composition of claim 3 wherein the 64 Zn-enriched zinc is present as a chelate of asparaginate.

6. The composition of claim 3 wherein the 64 Zn-enriched zinc is present as a chelate of aspartate.

7. The composition of claim 3 wherein the 64 Zn-enriched zinc is present as a chelate of glutamate.

8. A method of treating cancer in a patient in need of such treatment comprising the step of administering a composition of claim 1 to the patient.

9. A method of treating cancer in a patient in need of such treatment comprising the step of administering a composition of claim 3 to the patient.

10. A therapeutic composition comprising 64 Zn-enriched zinc present as a chelate of an amino acid, wherein the 64 Zn-enriched zinc is at least 90% 64 Zn and the composition contains between 0.6 mg and 330 mg of 64 Zn and further contains at least one excipient selected from an emulsifier, a detergent, a surfactant, a preservative, and DMSO.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: BALAKIN, OLEKSANDR
To: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
Reel/Frame 053484/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
To: VECTOR VITALE IP LLC
Reel/Frame 053484/0519 →
Continuity (3)
Continuation In Part 14833114 · Aug 23, 2015
Provisional Application 62123900 · Dec 1, 2014
Related Publication 20180055879A1 · Mar 1, 2018
Cited By (4)
US 12,233,089 US 12,527,819 US 12,527,820 US 12,734,240